WO2024252238A1 - Traitement du psoriasis - Google Patents

Traitement du psoriasis Download PDF

Info

Publication number
WO2024252238A1
WO2024252238A1 PCT/IB2024/055328 IB2024055328W WO2024252238A1 WO 2024252238 A1 WO2024252238 A1 WO 2024252238A1 IB 2024055328 W IB2024055328 W IB 2024055328W WO 2024252238 A1 WO2024252238 A1 WO 2024252238A1
Authority
WO
WIPO (PCT)
Prior art keywords
formulation
subject
class
phase
psoriasis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2024/055328
Other languages
English (en)
Inventor
Rafeek HASSEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hassen Mohammed Ameen
Original Assignee
Hassen Mohammed Ameen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hassen Mohammed Ameen filed Critical Hassen Mohammed Ameen
Priority to CN202480038351.3A priority Critical patent/CN121285366A/zh
Priority to EP24734116.7A priority patent/EP4724040A1/fr
Publication of WO2024252238A1 publication Critical patent/WO2024252238A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Definitions

  • Psoriasis is an inflammatory condition that is characterized by many different types of symptoms, most typically a rash with itchy, scaly patches, most commonly on the knees, elbows, trunk and scalp. Psoriasis is a common, long-term, i.e. chronic, skin disease. In addition, psoriasis symptoms can alternate between periods of flare ups, during which the symptoms are intense, and periods of remission during which the symptoms clear up. Remission periods last for an average of one to twelve months at a time.
  • Psoriasis may therefore be characterised in essentially three phases, i.e.: ⁇ an acute phase characterized by itching and breaking up of scales / rashes, ⁇ a scaly phase characterized by thickening and or discoloration of affected areas, and ⁇ a remission phase where there is no itching but mild scaling or dryness or redness of skin.
  • Table 1 Existing products used to treat psoriasis and the symptoms thereof
  • Product Ingredients Cosalic topical formula Salicylic Acid and Coal Tar Triderma psoriasis control Salicylic acid, Urea, Oat protein, Vit B & E Cera VE psoriasis cleanser Salicylic acid, Lactic Acid, Alpha Hydroxy Acid Mg 217 psoriasis ointment intensive Silver crumbs containing Coal Tar strength 113,4g Sonatur natural psoriasis cream Rose Geranium oil, Lanolin, white oil cosmetic grade Linotar cream Coal Tar, Vit E H&B natural PSO psoriasis cream Dead Sea minerals, Vit E, Aloe, Coconut & Olive Oil Dovate ointment Clobetasol Propionate Dovonex ointment Calcipotriene Vitamin D
  • Table 1 Existing products used to treat psoriasis and the symptoms thereof
  • Product Ingredients Cosalic topical formula Salicy
  • SUMMARY OF THE INVENTION ACCORDING TO A FIRST ASPECT OF THE INVENTION THERE IS PROVIDED a topical formulation comprising or consisting of, as active ingredients, one or more Class 6 Low Potency corticosteroid(s), an emulsifying ointment BP, honey, one or more natural oil(s), and optionally salicylic acid.
  • the topical formulation consists of, as active ingredients, one or more Class 6 Low Potency corticosteroid(s), an emulsifying ointment BP, honey, one or more natural oil(s) and optionally salicylic acid.
  • Class 6 Low Potency corticosteroids are well known to those skilled in the art.
  • the Class 6 Low Potency corticosteroid(s) may be selected from the group consisting of any one or more Class B, Triamcinolone Acetonide Type corticosteroid(s) or any one or more Class D, Betamethasone Dipropionate Type corticosteroid(s) or any combination thereof.
  • the Class B, Triamcinolone Acetonide Type corticosteroid(s) may be selected from any one or more of: Desonide 0.05% (w/w); Fluocinolone acetonide 0.01% (w/w); Triamcinolone acetonide 0.025% (w/w); or Triamcinolone diacetate 0.025% (w/w), or any combination thereof.
  • the Class D, Betamethasone Dipropionate Type corticosteroid(s) may be selected from any one or more of: Alclometasone dipropionate 0.05% (w/w); or Betamethasone valerate 0.1% (w/w), or any combination thereof.
  • the Class 6 Low Potency corticosteroid is fluocinolone acetonide.
  • the fluocinolone acetonide may have the chemical name pregna-1,4-diene-3,20-dione, 6,9-difluoro-11, 21- dihydroxy-16, 17- [ (1-methylethylidene) bis (oxy)]-, (6 ⁇ , 11 ⁇ , 16 ⁇ ) and the structural formula as shown in Formula I.
  • the formulation may comprise, by weight of the total formulation, from about 0.0025% to about 0.2%, including from about 0.0025% to about 0.025, of the Class 6 Low Potency corticosteroid.
  • the formulation comprises, by weight of the total formulation, between about 0.00625% and 0.01% of the Class 6 Low Potency corticosteroid, including about 0.0025% of the Class 6 Low Potency corticosteroid. In another possible embodiment of the invention, the formulation comprises, by weight of the total formulation, about 0.025% of the Class 6 Low Potency corticosteroid. In yet another possible embodiment of the invention, the formulation comprises about 0.2% by weight of the total formulation of the Class 6 Low Potency corticosteroid. In one possible embodiment of the invention, the Class 6 Low Potency corticosteroid is fluocinolone acetonide.
  • the one or more corticosteroid(s) may be formulated as a cream, a foam or an ointment.
  • the formulation may be an ointment.
  • the honey is preferably raw, unprocessed honey.
  • honey in the form in which it is present in a hive in which it is produced.
  • the formulation may comprise from about 5% to about 10%, by weight of the total formulation, of the honey.
  • the formulation may comprise about 5%, or about 6%, or about 7%, or about 8%, or about 9%, or about 10% by weight of the total formulation, of the honey.
  • the one or more natural oil(s) is preferably olive oil. More particularly, the olive oil is virgin olive oil extracted via a cold process method.
  • the formulation may comprise from about 5% to about 10%, by weight of the total formulation, of the one or more natural oil(s).
  • the formulation may comprise about 5%, or about 6%, or about 7%, or about 8%, or about 9%, or about 10% by weight of the total formulation, of the one or more natural oil(s).
  • the emulsifying ointment BP consists of: Emulsifying Wax – 30 % (w/w); White Soft Paraffin - 50% (w/w); and Liquid Paraffin – 20% (w/w).
  • the formulation comprises emulsifying ointment BP to make up the final formulation to 100% by weight of the total formulation.
  • the salicylic acid may, in particular, be that of Formula II Formula II
  • the formulation may comprise from about 2% to about 10%, by weight, of the salicylic acid.
  • the formulation may comprise about 2%, or about 3%, or about 4%, or about 5%, or about 6%, or about 7%, or about 8%, or about 9%, or about 10% by weight of the total formulation, of the salicylic acid.
  • the formulation may be in the form of a cream or an ointment.
  • the formulation may be an ointment.
  • ACCORDING TO A THIRD ASPECT OF THE INVENTION THERE IS PROVIDED a use of the compounds selected from the group comprising or consisting of: one or more Class 6 Low Potency corticosteroid(s), an emulsifying ointment BP, honey, one or more natural oil(s), and optionally salicylic acid as described in the first aspect of the invention in the manufacture of a formulation for the treatment of psoriasis or of at least one symptom arising from psoriasis in a subject in need thereof.
  • the subject is a human.
  • the formulation may be in the form of a cream or an ointment.
  • the formulation may be an ointment.
  • ACCORDING TO A FOURTH ASPECT OF THE INVENTION THERE IS PROVIDED a method of treating psoriasis or at least one symptom arising from psoriasis in a subject in need thereof, the method comprising topical application of the formulation according to the first aspect of the invention to an area of skin of the subject affected by psoriasis or at least one symptom arising from psoriasis.
  • the method may include a first step of selecting a particular formulation according to the first aspect of the invention wherein the particular formulation contains a concentration of the one or more Class 6 Low Potency corticosteroid(s) appropriate for a particular phase of psoriasis or symptom(s) thereof of the subject.
  • the particular phase may be selected from one of: an acute phase, typically characterized by itching, inflammation, scales and/or rashes; a scaly phase, typically characterized by thickening and/or discoloration of affected areas with scale formation; and a remission phase, where there is typically no itching but mild scaling, dryness and/or inflammation of skin.
  • the formulation may be an acute phase formulation having a concentration of the one or more Class 6 Low Potency corticosteroid(s) of about 0.0125% by weight.
  • salicylic acid is included in the formulation.
  • the formulation may comprise about 2%, or about 3%, or about 4%, or about 5%, or about 6%, or about 7%, or about 8%, or about 9%, or about 10% by weight of the total formulation, of the salicylic acid.
  • the formulation may be applied twice a day on affected areas of skin of the subject until resolution of acute phase symptoms of psoriasis whereupon the subject enters the remission phase, followed by a phased discontinuation of use of the acute phase formulation comprising once-daily application for about 5 days, followed by once-daily application on alternate days for the next about 10 days.
  • the subject may then use a formulation of the first aspect of the invention having a concentration of the one or more Class 6 Low Potency corticosteroid(s) of about 0.0025% by weight (i.e. a remission phase formulation) while in remission phase.
  • no salicylic acid is included in the remission phase formulation.
  • the concentration of the one or more Class 6 Low Potency corticosteroid(s) in the formulation may be about 0.00625% by weight (i.e. a scaly phase formulation) and the formulation may further comprise from about 2% to about 10%, by weight, of salicylic acid.
  • the formulation may comprise about 2%, or about 3%, or about 4%, or about 5%, or about 6%, or about 7%, or about 8%, or about 9%, or about 10% by weight of the total formulation, of the salicylic acid.
  • the scaly phase formulation may be applied twice a day on affected areas of skin of the subject until resolution of scaly phase symptoms of psoriasis, whereupon the subject enters the remission phase, followed by a phased discontinuation of use of the scaly phase formulation comprising once daily application for about 5 days, followed by once-daily application on alternate days for the next about 10 days.
  • the subject may then use a formulation of the invention having a concentration of the one or more Class 6 Low Potency corticosteroid(s) in of about 0.0025% by weight (i.e. a remission phase formulation) while in remission phase.
  • no salicylic acid is included in the remission phase formulation.
  • the concentration of the one or more Class 6 Low Potency corticosteroid(s) in the formulation may be about 0.0025% by weight (i.e. the remission formulation).
  • no salicylic acid is included in the remission phase formulation.
  • ⁇ P1 for Acute Phase ⁇ P2 for Scaly Phase ⁇ P3 for Remission Phase Treatment
  • P1 for acute phase treatment Formula for 100 g ⁇ Class 6 Low Potency corticosteroid such as fluocinolone acetonide - 0.0125% (w/w) ⁇ Raw Honey - 5% (w/w) ⁇ Olive Oil - 5% (w/w) ⁇ Emulsifying ointment BP to 100 g (w/w) ⁇
  • salicylic acid - 5% (w/w) If being included, first weigh out the salicylic acid and pulverize it to a powder.
  • P2 for scaly phase treatment Formula for 100 g ⁇ Class 6 Low Potency corticosteroid such as fluocinolone acetonide - 0.00625% (w/w) ⁇ Raw Honey - 5% (w/w) ⁇ Olive Oil - 5% (w/w) ⁇ Salicylic Acid - 5% (w/w) ⁇ Emulsifying ointment BP to 100 g (w/w)
  • P3 for remission phase treatment Formula for 100 g ⁇ Class 6 Low Potency corticosteroid such as fluocinolone acetonide - 0.0025% (w/w) ⁇ Raw Honey - 10% (w/w) ⁇ Olive Oil - 10% (w/w) ⁇ Emulsifying ointment BP to 100 g (w/w) Weigh out the required amount emulsifying ointment PB and add the Class 6 Low Potency corticosteroid 0.0025% (w/w) and mix thoroughly until combined. Finally add the honey and olive oil gradually, mixing continuously until homogenous.
  • the resultant product is a smooth, stable, pleasant fragrant cream that is applied sparingly twice a day only on the affected areas.
  • Treatment with this formulation for remission phase must be affected after treatment with formulations for acute phase and scaly phase.
  • the remission phase there is a desire aims to keep the skin ‘calm’ and therefore to prevent a relapse a very small amount of the Class 6 Low Potency corticosteroid of 0.0025% (w/w) was surprisingly found to be effective to prevent inflammation and remove the itching that may occur during the remission phase.
  • Case studies Case 1 A male adult, aged 50 years had been treated for about 1 year with a combination of commercially available medications, viz.
  • Chlorphenoxamine hydrochloride (Allergex®) cream; Nomospore (Bacitracin, Neomycin, Polymyxin B and Cocoa Butter, Cotton Seed Oil, Olive Oil, Sodium Pyruvate, Vitamin E, White Petrolatum); and Clobetasol propionate (Dovate®).
  • formulation P1 of the present invention the subject presented with itchy, broken skin including cuts on lower leg from acute phase psoriasis.
  • the subject reported experiencing relief of the itchiness in 2 to 3 days and the skin appearance showed less inflammation than at the start of treatment.
  • the cuts had started to heal and skin appearance showed less inflammation than at week 1 of treatment.
  • Chlorphenoxamine hydrochloride (Allergex®) tablets and cream Vaseline® (petroleum jelly, palmitic acid, stearic acid, mineral oil, glycerin, glyceryl stearate, cetyl alcohol, and potassium hydroxide); Dovonex® cream (calcipotriene monohydrate equivalent to 50 ⁇ g/g anhydrous calcipotriene in a cream base of cetearyl alcohol, ceteth-20, diazolidinyl urea, dichlorobenzyl alcohol, dibasic sodium phosphate, edetate disodium, dl-alpha tocopherol, glycerin, mineral oil, petrolatum.
  • Dovonex® cream calcipotriene monohydrate equivalent to 50 ⁇ g/g anhydrous calcipotriene in a cream base of cetearyl alcohol, ceteth-20, diazolidinyl urea, dichlorobenzyl alcohol, dibasic sodium phosphate, e
  • the subject presented with very dry, scaly and itchy skin from the ankle upwards on both legs from scaly phase psoriasis.
  • the subject reported experiencing relief of the itchiness and the skin appearance showed most scales had resolved compared to the start of treatment.
  • the subject was able to move to formulation P3 for maintenance of his psoriasis.
  • the subject had a slight flare-up and was treated for two days with formulation P1, which resolved the flare-up and the subject then was able to return to formulation P3 for maintenance of his psoriasis with no further flare- ups.
  • Case 3 A female child subject, aged 6 years had been treated for about 2 years with Unguentum emulsificans aquosum. At the time of first treatment with the remission formulation P3 of the present invention, the subject presented with very itchy inflamed patches of skin on the body. The subject reported relief within 1 week of treatment and has remained without symptoms for 6 months with the use of formulation P3.
  • Case 4 A female adult, aged 65 years had been treated for about 2 years with a combination of commercially available medications, viz.
  • SkincalmTM Infused oil (calendula, Oregon grape root, comfrey leaf, comfrey root, chamomile, olive oil), distilled water, shea butter, glycerin, beeswax, veg emulsifying wax, borage oil, emu oil, vitamin E, potassium sorbate); Zam-bukTM (paraffin wax, pale resin (colophony), eucalyptus oil, camphor, thyme oil, and sassafras oil).
  • the subject presented with dry, itchy skin on both shins with discolouration from psoriasis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une formulation topique comprenant en tant que principes actifs, un ou plusieurs corticostéroïdes à faible puissance de classe 6, une pommade émulsifiante BP, du miel, une ou plusieurs huile(s) naturelle(s), et éventuellement de l'acide salicylique, un procédé de production d'une telle formulation topique, et une méthode de traitement du psoriasis ou des symptômes de celui-ci chez un sujet avec l'application de la formulation topique de l'invention à un sujet en ayant besoin.
PCT/IB2024/055328 2023-06-06 2024-05-31 Traitement du psoriasis Ceased WO2024252238A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202480038351.3A CN121285366A (zh) 2023-06-06 2024-05-31 银屑病的治疗
EP24734116.7A EP4724040A1 (fr) 2023-06-06 2024-05-31 Traitement du psoriasis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ZA2023/05965 2023-06-06
ZA202305965 2023-06-06

Publications (1)

Publication Number Publication Date
WO2024252238A1 true WO2024252238A1 (fr) 2024-12-12

Family

ID=91585925

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2024/055328 Ceased WO2024252238A1 (fr) 2023-06-06 2024-05-31 Traitement du psoriasis

Country Status (4)

Country Link
EP (1) EP4724040A1 (fr)
CN (1) CN121285366A (fr)
WO (1) WO2024252238A1 (fr)
ZA (1) ZA202404593B (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2231007A1 (es) * 2003-10-13 2005-05-01 Alfredo Garcia Beltran Crema para el tratamiento de la psoriasis.
WO2007046113A2 (fr) * 2005-10-18 2007-04-26 Panacea Biotec Ltd. Composition pharmaceutique renfermant un ou plusieurs alcaloides et procede
US20090047359A1 (en) * 2007-08-13 2009-02-19 Jose Ramos Prieto Ointment for combating and treating skin diseases, and process for preparing said ointment

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2231007A1 (es) * 2003-10-13 2005-05-01 Alfredo Garcia Beltran Crema para el tratamiento de la psoriasis.
WO2007046113A2 (fr) * 2005-10-18 2007-04-26 Panacea Biotec Ltd. Composition pharmaceutique renfermant un ou plusieurs alcaloides et procede
US20090047359A1 (en) * 2007-08-13 2009-02-19 Jose Ramos Prieto Ointment for combating and treating skin diseases, and process for preparing said ointment

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MAN GEORGE ET AL: "Therapeutic Benefits of Natural Ingredients for Atopic Dermatitis", CHINESE JOURNAL OF INTEGRATED MEDICINE /ZHONGGUO JIEHE YIXUE ZAZHI (ENGLISH), ZHONGGUO ZHONG-XIYI JIEHE YANJIUHUI, CN, vol. 24, no. 4, 1 September 2017 (2017-09-01), pages 308 - 314, XP036489320, ISSN: 1672-0415, Retrieved from the Internet <URL:https://link.springer.com/article/10.1007/s11655-017-2769-1#Sec1> [retrieved on 20170901], DOI: 10.1007/S11655-017-2769-1 *

Also Published As

Publication number Publication date
CN121285366A (zh) 2026-01-06
ZA202404593B (en) 2025-02-26
EP4724040A1 (fr) 2026-04-15

Similar Documents

Publication Publication Date Title
US6667045B2 (en) Topical applications for skin treatment
EP0129003B1 (fr) Compositions cosmétiques et dermatologiques contenant du 1-alpha-hydroxycholecalciférol
US10596148B2 (en) Topical compositions for treatment of psoriasis
CN101304729A (zh) 皮肤病学中局部施用的水包油型乳液
RS55089B1 (sr) Korišćenje uljnih gelova sa triterpenima za zarastanje rana
US20080107758A1 (en) Topical steroid spray with botanic seed oils
US6375942B1 (en) Skin healing ointment
GB2453157A (en) Compositions and their use for treating skin conditions
PT1867322E (pt) Composição tópica para o tratamento da psoríase
RU2361594C2 (ru) Фармацевтические композиции, включающие комбинацию кальцитриола и клобетазола пропионат
US5707981A (en) Synergistic pharmaceutical compositions
EP3949980B1 (fr) Compositions pour le traitement de la dermatite atopique contenant des huiles ozonisées et des agents antioxydants naturels
WO2024252238A1 (fr) Traitement du psoriasis
US8936814B2 (en) Skin cream
WO2013158317A1 (fr) Formulations et procédés pour le traitement de maladies inflammatoires de la peau
DE102005008299B4 (de) Kosmetische und/oder dermatologische Formulierung, Verfahren zu deren Herstellung und Verwendung der Formulierung
KR20180092256A (ko) 민감성 피부용 보습 화장료 조성물
AU1432895A (en) Psoriasis treatment
US20090304603A1 (en) Topical steroid spray with botanic seed oils
RU2836917C1 (ru) Шампунь с экстрактом нафталанской нефти
RU2841821C1 (ru) Способ получения экстракта нафталанской нефти для приготовления шампуня
US20250319104A1 (en) Moisturizing cream for radiation dermatitis
WO2004014396A1 (fr) Medicament contenant de la fluocinolone et de la dexamethasone et/ou de l&#39;hydrocortisone et de la gentamicine et/ou de la neomycine
US20040022741A1 (en) Topical steroid spray
EP4543433A1 (fr) Composition de soins de la peau

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24734116

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: 2025571545

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2025571545

Country of ref document: JP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112025026639

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 202517130235

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2024734116

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 202517130235

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2024734116

Country of ref document: EP

Effective date: 20260107

WWE Wipo information: entry into national phase

Ref document number: 2025132660

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2024734116

Country of ref document: EP

Effective date: 20260107

ENP Entry into the national phase

Ref document number: 2024734116

Country of ref document: EP

Effective date: 20260107

ENP Entry into the national phase

Ref document number: 2024734116

Country of ref document: EP

Effective date: 20260107

ENP Entry into the national phase

Ref document number: 2024734116

Country of ref document: EP

Effective date: 20260107

WWP Wipo information: published in national office

Ref document number: 2025132660

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 112025026639

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20251203

WWP Wipo information: published in national office

Ref document number: 2024734116

Country of ref document: EP